Federal Register / Vol. 85, No. 229 / Friday, November 27, 2020 / Notices 76107 

2021. In addition, any person who has 

not entered an appearance as a party to 

the investigations may submit a written 

statement of information pertinent to 

the subject of the investigations, 

including statements of support or 

opposition to the petition, on or before 

March 25, 2021. On April 14, 2021, the 

Commission will make available to 

parties all information on which they 

have not had an opportunity to 

comment. Parties may submit final 

comments on this information on or 

before April 16, 2021, but such final 

comments must not contain new factual 

information and must otherwise comply 

with § 207.30 of the Commission’s rules. 

All written submissions must conform 

with the provisions of § 201.8 of the 

Commission’s rules; any submissions 

that contain BPI must also conform with 

the requirements of §§ 201.6, 207.3, and 

207.7 of the Commission’s rules. The 

Commission’s Handbook on Filing 

Procedures, available on the 

Commission’s website at https:// 

www.usitc.gov/documents/handbook_

on_filing_procedures.pdf, elaborates 

upon the Commission’s procedures with 

respect to filings. 

Additional written submissions to the 

Commission, including requests 

pursuant to § 201.12 of the 

Commission’s rules, shall not be 

accepted unless good cause is shown for 

accepting such submissions, or unless 

the submission is pursuant to a specific 

request by a Commissioner or 

Commission staff. 

In accordance with §§ 201.16(c) and 

207.3 of the Commission’s rules, each 

document filed by a party to the 

investigations must be served on all 

other parties to the investigations (as 

identified by either the public or BPI 

service list), and a certificate of service 

must be timely filed. The Secretary will 

not accept a document for filing without 

a certificate of service. 

Authority: These investigations are being 

conducted under authority of title VII of the 

Tariff Act of 1930; this notice is published 

pursuant to § 207.21 of the Commission’s 

rules. 

By order of the Commission. 

Issued: November 20, 2020. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2020–26164 Filed 11–25–20; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Open Source Imaging 

Consortium, Inc. 

Notice is hereby given that, on 

November 13, 2020, pursuant to Section 

6(a) of the National Cooperative 

Research and Production Act of 1993, 

15 U.S.C. 4301 et seq. (‘‘the Act’’), Open 

Source Imaging Consortium, Inc. 

(‘‘Open Source Imaging Consortium’’) 

has filed written notifications 

simultaneously with the Attorney 

General and the Federal Trade 

Commission disclosing changes in its 

membership. The notifications were 

filed for the purpose of extending the 

Act’s provisions limiting the recovery of 

antitrust plaintiffs to actual damages 

under specified circumstances. 

Specifically, Vida Diagnostics, Inc., 

Coralville, IA; and University of Genoa, 

Genoa, ITALY, have been added as 

parties to this venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and Open Source 

Imaging Consortium intends to file 

additional written notifications 

disclosing all changes in membership. 

On March 20, 2019, Open Source 

Imaging Consortium filed its original 

notification pursuant to Section 6(a) of 

the Act. The Department of Justice 

published a notice in the Federal 

Register pursuant to Section 6(b) of the 

Act on April 12, 2019 (84 FR 14973). 

The last notification was filed with 

the Department on August 19, 2020. A 

notice was published in the Federal 

Register pursuant to Section 6(b) of the 

Act on August 28, 2020 (85 FR 53402). 

Suzanne Morris, 

Chief, Premerger and Division Statistics, 

Antitrust Division. 

[FR Doc. 2020–26188 Filed 11–25–20; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–744] 

Importer of Controlled Substances 

Application: Meridian Medical 

Technologies 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Meridian Medical 

Technologies has applied to be 

registered as an importer of basic 

class(es) of controlled substance(s). 

Refer to Supplemental Information 

listed below for further drug 

information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before December 28, 2020. Such 

persons may also file a written request 

for a hearing on the application on or 

before December 28, 2020. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing must 

be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for a 

hearing should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on November 3, 2020, 

Meridian Medical Technologies, 2555 

Hermelin Drive, Saint Louis, Missouri 

63144, applied to be registered as an 

importer of the following basic class(es) 

of controlled substance(s): 

Controlled substance Drug code Schedule 

Morphine .................................................................................................................................................................. 9300 II 

The company manufactures a product 

containing morphine in the United 

States. The company exports this 

product to customers around the world. 

The company has been asked to ensure 

that its product, which is sold to 


jbell on DSKJLSW7X2PROD with NOTICES
76108 Federal Register / Vol. 85, No. 229 / Friday, November 27, 2020 / Notices 

European customers, meets the 

standards established by the European 

Pharmacopeia, administered by the 

Directorate for the quality of Medicines 

(EDQM). In order to ensure that its 

product will meet European 

specifications, the company seeks to 

import morphine supplied by EDQM for 

use as reference standards. No other 

activity for these drug codes is 

authorized for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2020–26172 Filed 11–25–20; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–743] 

Bulk Manufacturer of Controlled 

Substances Application: Novitium 

Pharma LLC 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Novitium Pharma LLC has 

applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

Supplemental Information listed below 

for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before January 26, 2021. Such 

persons may also file a written request 

for a hearing on the application on or 

before January 26, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on November 2, 2020, 

Novitium Pharma LLC, 70 Lake Drive, 

East Windsor, New Jersey 08520, 

applied to be registered as a bulk 

manufacturer of the following basic 

class(es) of controlled substances: 

Controlled substance Drug 

code Schedule 

Levorphanol ..................... 9220 II 

The company plans to bulk 

manufacture the above-controlled 

substance to support production of the 

company’s Food and Drug 

Administration approved drug product. 

No other activity for this drug code is 

authorized for this registration. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2020–26171 Filed 11–25–20; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–746] 

Importer of Controlled Substances 

Application: Noramco Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Noramco Inc. has applied to 

be registered as an importer of basic 

class(es) of controlled substance(s). 

Refer to Supplemental Information 

listed below for further drug 

information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before December 28, 2020. Such 

persons may also file a written request 

for a hearing on the application on or 

before December 28, 2020. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing must 

be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for a 

hearing should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on October 23, 2020, 

Noramco Inc., 500 Swedes Landing 

Road, Wilmington, Delaware, 19801– 

4417, applied to be registered as an 

importer of the following basic class(es) 

of controlled substance(s): 

Controlled substance Drug 

code Schedule 

Marihuana ........................ 7360 I 

Tetrahydrocannabinols .... 7370 I 

Nabilone .......................... 7379 II 

Phenylacetone ................. 8501 II 

Opium, Raw ..................... 9600 II 

Poppy Straw Concentrate 9670 II 

Tapentadol ...................... 9780 II 

The company plans to import 

Phenylacetone (8501), and Poppy Straw 

Concentrate (9670) to bulk manufacture 

other controlled substances for 

distribution to its customers. The 

company plans to import an 

intermediate form of Tapentadol (9780) 

to bulk manufacture Tapentadol for 

distribution to its customers. In 

reference to drug codes 7360 

(Marihuana) and 7370 

(Tetrahydrocannabinols), the company 

plans to import a synthetic cannabidiol 

and a synthetic Tetrahydrocannabinol. 

No other activity for these drug codes is 

authorized for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2020–26174 Filed 11–25–20; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–742] 

Importer of Controlled Substances 

Application: Lyndra Therapeutics 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Lyndra Therapeutics has 

applied to be registered as an importer 

of basic class(es) of controlled 

substance(s). Refer to Supplemental 

Information listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 


jbell on DSKJLSW7X2PROD with NOTICES